Purification and characterization of human immunodeficiency virus type 1 nef gene product expressed by a recombinant baculovirus. 1991

Y Matsuura, and M Maekawa, and S Hattori, and N Ikegami, and A Hayashi, and S Yamazaki, and C Morita, and Y Takebe
Department of Veterinary Science, National Institute of Health, Tokyo, Japan.

We have constructed the recombinant baculovirus which expresses the human immunodeficiency virus type 1 negative factor (nef) gene. Spodoptera frugiperda cells infected with the recombinant virus produced a 27-kDa protein which reacted with rabbit antisera raised against a carboxy-terminal synthetic peptide of the Nef protein by immunoblot analysis. Labeling experiment showed that the recombinant Nef protein was myristoylated. The recombinant Nef protein was purified to near homogeneity by DEAE-Sephacel, phenyl-Sepharose 4B, blue-Sepharose, and Sephadex G-150 column chromatography. No detectable GTP binding activity was observed in the purified recombinant Nef product.

UI MeSH Term Description Entries
D009036 Moths Insects of the suborder Heterocera of the order LEPIDOPTERA. Antheraea,Giant Silkmoths,Giant Silkworms,Silkmoths, Giant,Silkworms, Giant,Antheraeas,Giant Silkmoth,Giant Silkworm,Moth,Silkmoth, Giant,Silkworm, Giant
D009227 Myristic Acids 14-carbon saturated monocarboxylic acids. Tetradecanoic Acids,Acids, Myristic,Acids, Tetradecanoic
D011499 Protein Processing, Post-Translational Any of various enzymatically catalyzed post-translational modifications of PEPTIDES or PROTEINS in the cell of origin. These modifications include carboxylation; HYDROXYLATION; ACETYLATION; PHOSPHORYLATION; METHYLATION; GLYCOSYLATION; ubiquitination; oxidation; proteolysis; and crosslinking and result in changes in molecular weight and electrophoretic motility. Amino Acid Modification, Post-Translational,Post-Translational Modification,Post-Translational Protein Modification,Posttranslational Modification,Protein Modification, Post-Translational,Amino Acid Modification, Posttranslational,Post-Translational Amino Acid Modification,Post-Translational Modifications,Post-Translational Protein Processing,Posttranslational Amino Acid Modification,Posttranslational Modifications,Posttranslational Protein Processing,Protein Processing, Post Translational,Protein Processing, Posttranslational,Amino Acid Modification, Post Translational,Modification, Post-Translational,Modification, Post-Translational Protein,Modification, Posttranslational,Modifications, Post-Translational,Modifications, Post-Translational Protein,Modifications, Posttranslational,Post Translational Amino Acid Modification,Post Translational Modification,Post Translational Modifications,Post Translational Protein Modification,Post Translational Protein Processing,Post-Translational Protein Modifications,Processing, Post-Translational Protein,Processing, Posttranslational Protein,Protein Modification, Post Translational,Protein Modifications, Post-Translational
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D006160 Guanosine Triphosphate Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety. GTP,Triphosphate, Guanosine
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated

Related Publications

Y Matsuura, and M Maekawa, and S Hattori, and N Ikegami, and A Hayashi, and S Yamazaki, and C Morita, and Y Takebe
July 1990, Journal of virology,
Y Matsuura, and M Maekawa, and S Hattori, and N Ikegami, and A Hayashi, and S Yamazaki, and C Morita, and Y Takebe
May 1996, [Hokkaido igaku zasshi] The Hokkaido journal of medical science,
Y Matsuura, and M Maekawa, and S Hattori, and N Ikegami, and A Hayashi, and S Yamazaki, and C Morita, and Y Takebe
May 1992, European journal of biochemistry,
Y Matsuura, and M Maekawa, and S Hattori, and N Ikegami, and A Hayashi, and S Yamazaki, and C Morita, and Y Takebe
November 1994, The Journal of general virology,
Y Matsuura, and M Maekawa, and S Hattori, and N Ikegami, and A Hayashi, and S Yamazaki, and C Morita, and Y Takebe
March 1994, The Journal of general virology,
Y Matsuura, and M Maekawa, and S Hattori, and N Ikegami, and A Hayashi, and S Yamazaki, and C Morita, and Y Takebe
February 1991, Journal of virology,
Y Matsuura, and M Maekawa, and S Hattori, and N Ikegami, and A Hayashi, and S Yamazaki, and C Morita, and Y Takebe
October 1990, Proceedings of the National Academy of Sciences of the United States of America,
Y Matsuura, and M Maekawa, and S Hattori, and N Ikegami, and A Hayashi, and S Yamazaki, and C Morita, and Y Takebe
January 1994, Journal of virology,
Y Matsuura, and M Maekawa, and S Hattori, and N Ikegami, and A Hayashi, and S Yamazaki, and C Morita, and Y Takebe
July 1999, Journal of virology,
Y Matsuura, and M Maekawa, and S Hattori, and N Ikegami, and A Hayashi, and S Yamazaki, and C Morita, and Y Takebe
December 1993, AIDS research and human retroviruses,
Copied contents to your clipboard!